Clinical application progress of bendamustine in lymphocytic malignancy

VernacularTitle:苯达莫司汀在淋巴系统恶性肿瘤中的临床应用进展
Author: Jun MA
Publication Type:Journal Article
Keywords: Bendamustine; Lymphocytic malignancy
From: Journal of Leukemia & Lymphoma 2016;25(4):193-198
CountryChina
Language:Chinese
Abstract: Bendamustine hydrochloride is a bifunctional alkylating agent with clinical activity to a number of cancers.Bendamustine,an emerging nitrogen mustards anticancer agent,can improve tolerability without sacrificing clinical activity.Although bendamustine has been used widely for more than 40 years,it was not systematically studied in lymphoproliferative disorders until the 1990s.Bendamustine molecule is more stable than the molecules of other alkylators,and it can cause more extensive and more durable damage to DNA.Unlike other alkylating agents,primary targets of bendamustine are based on excision repair pathways rather than mismatch repair pathways,and it activates DNA damage stress responses,induces apoptosis,inhibits mitotic checkpoints,and induces mitotic catastrophe.This paper will review the role of bendamustine in chronic lymphoblastic leukemia(CLL),indolent non-Hodgkin's lymphoma (NHL),diffuse large B-cell lymphoma (DLBCL),mantle cell lymphoma (MCL),peripheral T-cell lymphoma (PTCL),and Hodgkin' s lymphoma (HL).